passa ai contenuti
Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance Anteprima di questo documento
ChiudiAnteprima di questo documento
Stiamo controllando…

Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance

Autore: Benjamin Bonavida
Editore: New York, NY : Springer, 2013.
Serie: Resistance to targeted anti-cancer therapeutics, v.2
Edizione/Formato:   eBook : Document : EnglishVedi tutte le edizioni e i formati
Banca dati:WorldCat
Sommario:
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops  Per saperne di più…
Voto:

(non ancora votato) 0 con commenti - Diventa il primo.

Soggetti
Altri come questo

 

Trova una copia online

Collegamenti a questo documento

Trova una copia in biblioteca

&AllPage.SpinnerRetrieving; Stiamo ricercando le biblioteche che possiedono questo documento…

Dettagli

Genere/forma: Electronic books
Tipo materiale: Document, Risorsa internet
Tipo documento: Internet Resource, Computer File
Tutti gli autori / Collaboratori: Benjamin Bonavida
ISBN: 9781461476542 1461476542
Numero OCLC: 857224719
Note: Includes index.
Descrizione: 1 online resource (xiii, 202 pages) : illustrations.
Contenuti: Resistance to Anticancer Antibodies: From Mechanisms to Solutions / Lina Reslan, Charles Dumontet --
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence / Yangyang Wang, Francesco Sabbatino, Ling Yu --
Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors / Emily L. Williams, Sean H. Lim --
Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance / Francisco J. Hernandez-Ilizaliturri --
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype / Benjamin Bonavida --
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer / Zacharenia Saridaki, John Souglakos --
Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors / Peter Hersey, Stuart Gallagher --
Strategies to Overcome TRAIL Resistance in Cancer / Simone Fulda --
Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics / Vaughn Smider --
Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance? / Penelope M. Drake, David Rabuka.
Titolo della serie: Resistance to targeted anti-cancer therapeutics, v.2
Responsabilità: Benjamin Bonavida, editor.
Maggiori informazioni:

Abstract:

Resistance to Immunotherapeutic Antibodies in Cancer  Per saperne di più…

Commenti

Commenti degli utenti
Recuperando commenti GoodReads…
Stiamo recuperando commenti DOGObooks

Etichette

Diventa il primo.
Conferma questa richiesta

Potresti aver già richiesto questo documento. Seleziona OK se si vuole procedere comunque con questa richiesta.

Dati collegati


<http://www.worldcat.org/oclc/857224719>
library:oclcnum"857224719"
library:placeOfPublication
owl:sameAs<info:oclcnum/857224719>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:datePublished"2013"
schema:description"The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1754943023>
schema:genre"Electronic books."
schema:inLanguage"en"
schema:name"Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance"
schema:url<http://lib.myilibrary.com?id=517004>
schema:url
schema:url
schema:url<http://site.ebrary.com/id/10743790>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=622877>
schema:workExample
schema:workExample

Content-negotiable representations

Chiudi finestra

Per favore entra in WorldCat 

Non hai un account? Puoi facilmente crearne uno gratuito.